Literature DB >> 12238836

Combined surgical and endovascular treatment of acute aortic dissection type A: preliminary results.

Tatjana Fleck1, Doris Hutschala, Martin Czerny, Marek P Ehrlich, Marie-Theres Kasimir, Manfred Cejna, Ernst Wolner, Martin Grabenwoger.   

Abstract

BACKGROUND: The established treatment modality of acute Stanford type A dissection includes repair of the ascending aorta and various portions of the aortic arch, whereas the descending aorta is left untreated. We report a simultaneous approach of open repair of the ascending aorta with transluminal stent grafting of the descending aorta to minimize the consequences of an untreated descending aorta.
METHODS: From April 2001 to February 2002, 8 consecutive patients (3 women [37.5%] and 5 men [62.5%]) with a mean age of 55.7 years (range, 45 to 70 years) were intended to be treated with the combined method of surgical repair of the ascending aorta and transluminal stent grafting into the descending aorta during the period of deep hypothermic circulatory arrest. Circulatory arrest time ranged between 30 and 67 minutes (average, 38.8 minutes). Specially designed Talent stent grafts (32 to 40 mm in diameter, length 13 cm) were inserted under direct vision and deployed with the proximal end at the origin of the left subclavian artery.
RESULTS: Intraoperative stent graft placement was successful in 7 patients (87.5%). Because of severe kinking of the distal arch, stent insertion failed in 1 patient (12.5%). One patient with a history of preoperative stroke in the middle cerebral artery died because of intracerebral bleeding on postoperative day 2, resulting in an in-hospital mortality of 12.5%. Mean intensive care unit stay was 6.4 days (range, 2 to 21 days) and overall hospital stay was 18.2 days (range, 7 to 33 days). Completion computed tomographic scans revealed complete thrombosis of the false lumen in 2 patients and partial thrombosis in 4 patients. Follow-up was complete and ranged from 1 to 9 months (mean, 5.4 months).
CONCLUSIONS: This preliminary study shows that combined surgical and endovascular treatment of acute type A dissection is feasible, and at least partial thrombosis of the false lumen can be achieved, potentially minimizing the risk of further dilatation or rupture. Additionally, the stent graft expands the otherwise sickle-shaped true lumen, thereby ameliorating distal aortic perfusion. Long-term results are warranted to demonstrate the effectiveness of this new combined treatment modality.

Entities:  

Mesh:

Year:  2002        PMID: 12238836     DOI: 10.1016/s0003-4975(02)03745-1

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  5 in total

1.  We should replace the aortic arch and more in DeBakey type I dissection - A perspective from the Cleveland Clinic.

Authors:  Eric E Roselli
Journal:  Ann Cardiothorac Surg       Date:  2013-03

2.  Overall Essen's experience with the E-vita open hybrid stent graft system and evolution of the surgical technique.

Authors:  Konstantinos Tsagakis; Daniel Dohle; Jaroslav Benedik; Helmut Lieder; Heinz Jakob
Journal:  Ann Cardiothorac Surg       Date:  2013-09

3.  Traumatic ascending aortopulmonary window following pulmonary artery stent dilatation: therapy with aortic endovascular stent graft.

Authors:  G Ailawadi; D S Lim; B B Peeler; A H Matsumoto; M D Dake
Journal:  Pediatr Cardiol       Date:  2007-05-25       Impact factor: 1.838

4.  Cardiac and Vascular Surgeons for the Treatment of Aortic Disease: A Successful Partnership for Decision-Making and Management of Complex Cases.

Authors:  Massimo Capoccia; Soumik Pal; Michael Murphy; Maziar Mireskandari; Andreas Hoschtitzky; Christoph A Nienaber; Nicholas J Cheshire; Ulrich P Rosendahl
Journal:  J Investig Med High Impact Case Rep       Date:  2021 Jan-Dec

5.  Relationship between the extent of aortic replacement and stent graft for acute DeBakey type I aortic dissection and outcomes: Results from a medical center in Taiwan.

Authors:  Chiao-Po Hsu; Chun-Yang Huang; Fei-Yi Wu
Journal:  PLoS One       Date:  2019-01-04       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.